Royalties increased by 33% to $92.2 million in the third quarter of 2020, compared to the same quarter in 2019. Invested an additional $12.5 million into the common stock and warrants of Entasis Therapeutics Holding Inc. (NASDAQ: ETTX), a leader in anti-infectives development. BURLINGAME, Calif.

New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm LONDON & BURLINGAME, Calif. --(BUSINESS WIRE)--Sep. 9, 2020-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration

Royalties increased by 7% to $72.4 million in the second quarter of 2020, compared to the same quarter in 2019. Pavel Raifeld named as Chief Executive Officer. Invested $35 million into common stock and warrants of Entasis Therapeutics Holding Inc. (NASDAQ: ETTX), a leader in anti-infectives

WALTHAM, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the closing of the second tranche of the $35

Pavel Raifeld to continue the implementation of the Company’s strategy and focus on value creation for shareholders BURLINGAME, Calif. --(BUSINESS WIRE)--May 21, 2020-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva”) today announced the appointment of Pavel Raifeld as Chief Executive Officer effective

Total net revenue increased by 43% to $78.7 million in the first quarter of 2020, compared to the same quarter in 2019. Income before income taxes increased by 96% to $94.9 million in the first quarter of 2020, compared to the same quarter in 2019. BURLINGAME, Calif. --(BUSINESS WIRE)--Apr.

BURLINGAME, Calif. --(BUSINESS WIRE)--Mar. 31, 2020-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”) announced today that, due to the public health impact of the coronavirus pandemic, the location of the Company’s 2020 annual meeting of stockholders has been changed and will be held in

- Funds to be used primarily to advance its lead Pseudomonas aeruginosa candidate, AP-PA02 MARINA DEL REY, Calif. , March 30, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage

Submission supported by pivotal CAPTAIN study demonstrating statistically significant improvement in lung function compared with the ICS/LABA, Relvar/Breo Ellipta At least 30% of asthma patients continue to experience symptoms even when adherent to ICS/LABA treatment LONDON --(BUSINESS WIRE)--Feb.

Total net revenue decreased by 4.9% to $76.0 million in the fourth quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased by 3.9% to $70.3 million in the fourth quarter of 2019, compared to the same quarter in 2018. BURLINGAME, Calif. --(BUSINESS WIRE)--Feb.